CYP19A1 and breast cancer: Endocrine therapy, using selective estrogen receptor modulators (SERMs), such as tamoxifen, selective estrogen receptor downregulators (SERDs), such as fulvestrant, or aromatase inhibitors (AIs), has prolonged the lives of millions of ERα-positive breast cancer patients and has been a great clinical success [10].